DNA Link Inc (127120) - Total Liabilities

Latest as of December 2025: ₩54.44 Billion KRW ≈ $36.90 Million USD

Based on the latest financial reports, DNA Link Inc (127120) has total liabilities worth ₩54.44 Billion KRW (≈ $36.90 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DNA Link Inc (127120) cash conversion ratio to assess how effectively this company generates cash.

DNA Link Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how DNA Link Inc's total liabilities have evolved over time, based on quarterly financial data. Check 127120 financial resilience to evaluate the company's liquid asset resilience ratio.

DNA Link Inc Competitors by Total Liabilities

The table below lists competitors of DNA Link Inc ranked by their total liabilities.

Company Country Total Liabilities
Prima Andalan Mandiri Tbk PT
JK:MCOL
Indonesia Rp158.96 Million
STEVANATO GROUP SPA O.N.
F:87N
Germany €1.06 Billion
Zhejiang Shengyang Science
SHG:603703
China CN¥1.10 Billion
Shanxi Zhendong Pharmaceutical
SHE:300158
China CN¥882.65 Million
Shinry Technologies Co Ltd Class A
SHE:300745
China CN¥2.11 Billion
Total Gabon
F:RZW
Germany €1.62 Billion
Jiangsu Yawei Machine Tool Co Ltd
SHE:002559
China CN¥2.99 Billion
Jiayuan Science and Technology Co.Ltd.
SHE:301117
China CN¥222.17 Million

Liability Composition Analysis (2011–2025)

This chart breaks down DNA Link Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 127120 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.14 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.79 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.44 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how DNA Link Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for DNA Link Inc (2011–2025)

The table below shows the annual total liabilities of DNA Link Inc from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩54.44 Billion
≈ $36.90 Million
+85.46%
2024-12-31 ₩29.36 Billion
≈ $19.89 Million
+135.23%
2023-12-31 ₩12.48 Billion
≈ $8.46 Million
-20.09%
2022-12-31 ₩15.62 Billion
≈ $10.58 Million
+89.40%
2021-12-31 ₩8.25 Billion
≈ $5.59 Million
-40.42%
2020-12-31 ₩13.84 Billion
≈ $9.38 Million
-14.77%
2019-12-31 ₩16.24 Billion
≈ $11.00 Million
+5.02%
2018-12-31 ₩15.46 Billion
≈ $10.48 Million
+996.65%
2017-12-31 ₩1.41 Billion
≈ $955.48K
-94.14%
2016-12-31 ₩24.04 Billion
≈ $16.29 Million
+11.69%
2015-12-31 ₩21.53 Billion
≈ $14.59 Million
+68.92%
2014-12-31 ₩12.74 Billion
≈ $8.64 Million
+3.34%
2012-12-31 ₩12.33 Billion
≈ $8.36 Million
+37.43%
2011-12-31 ₩8.97 Billion
≈ $6.08 Million
--

About DNA Link Inc

KQ:127120 Korea Biotechnology
Market Cap
$830.39 Million
₩1.23 Trillion KRW
Market Cap Rank
#9964 Global
#289 in Korea
Share Price
₩40800.00
Change (1 day)
-0.73%
52-Week Range
₩8340.00 - ₩48900.00
All Time High
₩48900.00
About

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more